Displaying drugs 2301 - 2325 of 3223 in total
AGN-201904
Agn 201904 has been used in trials studying the prevention of Peptic Ulcer.
Investigational
RP-L201
Investigational
Poliglusam
Poliglusam, or chitosan, is a linear polysaccharide consisting of D-glucosamine and N-acetyl-D-glucosamine. Naturally-occuring poliglusam is found in the cell walls of fungi, soil and sediments where it is produced from degradation of chitin induced by certain groups of bacteria that produce the enzymes deacetylase or chitosanase enzymes . In comparison,...
Experimental
Izaflortaucipir
Investigational
Matched Iupac: … 11-(2-fluoropyridin-4-yl)-4,8,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaene …
Delgocitinib
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
Investigational
Matched Description: … clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 …
Linseed oil
Linseed oil is a rich source of α-Linolenic acid extracted from the dried, ripened seeds of the flax plant Linum usitatissimum. Other fatty acids contained in linseed oil include palmitic acid, stearic acid, oleic acid and linolenic acid. Linseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen...
Investigational
Matched Mixtures name: … aspen nutrition Omega 3-6-9 …
CCX915
CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and...
Investigational
BMS-986094
INX-08189 has been used in trials studying the treatment of Hepatitis C, HCV (Genotype 1), and Hepatitis C Virus.
Investigational
Matched Iupac: … 2,2-dimethylpropyl (2S)-2-[({[(2R,3R,4R,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan …
BMS-929075
BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).
Investigational
BMS-919373
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
Investigational
BMS-986158
BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
Investigational
TNG908
TNG908 is a small molecule inhibitor of protein arginine methyl transferase 5 (PRMT5).
Investigational
Edotreotide yttrium Y-90
Investigational
Prinomastat
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Matched Description: … Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing …
TK-112690
Investigational
RGX-181
RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene. Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Investigational
Matched Description: … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble …
AX200
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
GO-203-2C
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
ER2001
Investigational
LX2006
Investigational
LT2003
Investigational
Yttrium Y-90 epratuzumab tetraxetan
Investigational
Displaying drugs 2301 - 2325 of 3223 in total